S
Splisense
Biotech & Life Sciences · Jerusalem, Israel · Founded 2016
Developing transformative RNA-based treatments for unmet needs relating to CF and other genetic pulmonary illnesses MoreLess
SpliSense is a clinical-stage biotechnology company focused on developing transformative RNA-based treatments for unmet needs in diverse pulmonary diseases. Utilizing clinically validated Antisense Oligonucleotide (ASO) technology, SpliSense delivers its treatments non-invasively by inhalation directly to the lungs. The company is engaged in various stages of drug development, from discovery to Investigational New Drug (IND) applications. SpliSense primarily serves patients suffering from severe pulmonary conditions such as Cystic Fibrosis (CF) and Idiopathic Pulmonary Fibrosis (IPF). The company's business model revolves around the research, development, and commercialization of its innovative therapies. Revenue is generated through partnerships, licensing agreements, and eventual sales of approved treatments.
Keywords: RNA-based treatments, pulmonary diseases, Antisense Oligonucleotide, inhalation delivery, clinical-stage, Cystic Fibrosis, Idiopathic Pulmonary Fibrosis, biotechnology, drug development, non-invasive therapy.
Company overview
Splisense company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2016
- Headquarters
- Jerusalem, Israel
- Employees
- 16
- Open positions
- None listed
- Dealroom signal
- 42.8
Valuation & funding
Splisense funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANT✓Other financing | Jun 2026 | $13M | — | Cystic Fibrosis Foundation | ↗ |
| SERIES B✓Equity / VC | May 2021 | $29M | $114M | Biotel Limited · OrbiMed · Israel Biotech Fund · Cystic Fibrosis Foundation | — |
| SPINOUT✓Other financing | Jan 2016 | $0 | — | The Hebrew University of Jerusalem · Yissum Research Development | ↗ |
| SEED✓Equity / VC | Jan 2016 | $0 | — | Integra Holdings | — |
Financials
Workforce over time
Available workforce history. Financial fields without reported data are omitted.
| Year | Employees |
|---|---|
| 2026 | 16 |
| 2025 | 16 |
| 2024 | 15 |
| 2023 | 15 |
| 2022 | 12 |
| 2021 | 7 |
Growth signals
Splisense website traffic
Latest recorded traffic for Splisense is 2.6K monthly website visits, up 23.8% over the last three months. Splisense's team grew 0% over the past year.
Comparisons
Splisense compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Splisense's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Splisense has talent and traffic
team presence
In the news
Latest news about Splisense
Recent press, funding announcements, and product moves mentioning Splisense — open to read from the original sources.
Market sentiment
What the market is saying about Splisense
An AI-synthesized read of the highest-engagement posts about Splisense on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Splisense’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.